Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
4D Molecular Therapeutics, Inc. (FDMT) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/16/2023 EFFECT Form EFFECT - Notice of Effectiveness:
08/09/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
08/09/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/09/2023 8-K Quarterly results
Docs: "4D Molecular Therapeutics Reports Second Quarter 2023 Financial Results and Operational Highlights • Presented positive interim data from intravitreal 4D-150 Phase 1/2 PRISM clinical trial for patients with wet age-related macular degeneration • Completed target enrollment of 50 patients in the randomized Phase 2 Dose Expansion stage of the PRISM clinical trial in July, nearly two quarters ahead of initially projected enrollment completion • Presented positive interim data from aerosolized 4D-710 Phase 1/2 AEROW clinical trial for patients with cystic fibrosis lung disease • Anticipate multiple clinical data and regulatory interaction updates onlead clinical-stage product candidates 4D-150 in wet AMD and 4D-710 in cystic fibrosis lung disease over the next 12 mo..."
05/25/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/10/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/10/2023 8-K Quarterly results
Docs: "4D Molecular Therapeutics Reports First Quarter 2023 Financial Results and Operational Highlights • Presented positive interim data from intravitreal 4D-150 Phase 1/2 PRISM clinical trial for wet age-related macular degeneration at the 2023 ARVO Annual Meeting • On track for completion of enrollment of the Phase 2 Dose Expansion Stage of the PRISM clinical trial in Q3 2023 • Acquired all worldwide rights to short-form human complement factor H from Aevitas Therapeutics, Inc. and announced sCFH as payload for 4D-175 lead product candidate for geographic atrophy • Multiple additional clinical data updates on clinical-stage product candidates expected later in 2023, including on 4D-710 for cystic fibrosis lung disease in Q2 2023 • Closed upsized public offer..."
05/09/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Underwriting Agreement, among 4D Molecular Therapeutics, Inc. and Goldman Sachs & Co. LLC, BofA Securities, Inc. and Evercore Group, L.L.C",
"Opinion of Latham & Watkins LLP"
05/08/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
05/04/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
05/03/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
04/21/2023 144 Form 144 - Report of proposed sale of securities:
04/21/2023 144 Form 144 - Report of proposed sale of securities:
03/15/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/15/2023 8-K Quarterly results
Docs: "4D Molecular Therapeutics Reports Full Year 2022 Financial Results and Operational Highlights • Provided updates on clinical pipeline, including 4D-150 for wet age-related macular degeneration and diabetic macular edema , 4D-710 for cystic fibrosis lung disease, and 4D-310 for Fabry disease cardiomyopathy • Demonstrated robust clinical gene delivery, tolerability and initial biological activity with first three customized and evolved vectors generated from Therapeutic Vector Evolution platform • Expanded preclinical pipeline with large market geographic atrophy and alpha-1 antitrypsin deficiency lung disease programs • On track for multiple clinical data updates on lead clinical-stage product candidates during 2023 • Cash, cash equivalents and marketable ..."
03/15/2023 10-K Annual Report for the period ended December 31, 2022
02/14/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/09/2023 SC 13G/A JANUS HENDERSON GROUP PLC reports a 4.5% stake in 4D Molecular Therapeutics, Inc.
02/08/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
01/31/2023 SC 13G/A BlackRock Inc. reports a 7.7% stake in 4D Molecular Therapeutics Inc.
01/26/2023 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
11/09/2022 8-K Quarterly results
11/08/2022 10-Q Quarterly Report for the period ended September 30, 2022
09/27/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
09/07/2022 EFFECT Form EFFECT - Notice of Effectiveness:
08/22/2022 S-3 Form S-3 - Registration statement under Securities Act of 1933:
08/11/2022 8-K Quarterly results
08/11/2022 10-Q Quarterly Report for the period ended June 30, 2022
06/21/2022 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
06/17/2022 8-K Quarterly results
05/27/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
05/12/2022 10-Q Quarterly Report for the period ended March 31, 2022
04/18/2022 EFFECT Form EFFECT - Notice of Effectiveness:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy